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Background
Blood pressure (BP) is characterized by a circadian pattern, with higher pressure during the diurnal period than during the nocturnal period [1] . This circadian BP variability (BPV) is related to the imbalance between cardiac output and systemic resistance [2] and is influenced by the autonomic nervous system [3, 4] . A non-dipping profile is defined by a blunted fall in BP (less than 10%) during the nocturnal period and has been observed in various clinical conditions, including systemic hypertension, diabetes and renal failure [5] [6] [7] [8] [9] . The non-dipping profile is also associated with poor prognosis in hypertensive or diabetic patients but also in the general population [9] [10] [11] . In systemic hypertension, non-dipper patients display a worse haemodynamic profile, a higher left ventricular (LV) mass index and greater peripheral organ damage compared with dipper patients [9, 12] .
Familial amyloid polyneuropathy (FAP) is an autonomic dominant disease induced by the misfolding of a mutated protein, transthyretin (TTR) [13, 14] . More than 100 different TTR mutations are currently described, with various clinical presentations [15] . In Europe, several geographical foci are reported (Portugal, Sweden) and the most common mutation is the Val30Met mutation [16] . Polyneuropathy due to FAP includes autonomic nervous system impairment and cardiac denervation [17, 18] . This cardiac autonomic denervation is associated with lower circadian BPV at the early stages of FAP [19] . However, cardiopathy due to FAP includes not only cardiac denervation, but also conduction disorders, increased wall thickness and, later in the course of the disease, haemodynamic impairment with restrictive pattern [20] [21] [22] . The precise relationship between these various components of cardiac involvement and BPV is still unknown.
The aim of our study was to document BPV in FAP patients with various mutation types. We tested the hypothesis that low BPV reflects the severity of cardiac disease in FAP, namely haemodynamic impairment, wall thickening due to amyloid infiltration, conduction disorders and cardiac denervation.
Methods
Our retrospective, single-centre study included consecutive FAP patients hospitalized from September 2009 to April 2011. Patients were recruited through the French Reference Centre for Familial Amyloid Polyneuropathy and other Rare Peripheral Neuropathies. One patient with arterial hypertension was excluded from the study and 49 FAP patients entered the final analysis. All patients had high quality ambulatory BP monitoring, which is part of our routine protocol in FAP. The FAP diagnosis was confirmed by TTR genotyping. Eleven different TTR mutations were documented and the TTR mutation type was Val30Met in 28 over 49 patients (57%). Ambulatory BP data were also obtained in 49 age-and sex-matched control subjects. Control subjects were patients who were referred for suspicion of arterial hypertension but in whom this diagnosis was ruled out; the subjects were also free from antihypertensive treatment. The study complied with the Declaration of Helsinki and informed consent was obtained from all patients.
Clinical status was evaluated by the polyneuropathy disability (PND) score as previously described [23] . Briefly, a PND score I indicates preserved walking ability; II indicates that walking is impaired but that the patient is able to walk without a stick or crutch; III means that the patient walks with the help of one (or two) stick(s) or crutch(es); and IV means that patient is unable to walk even with help.
Ambulatory BP monitoring was performed in all FAP patients according to the European Society of Cardiology guidelines [24] . The BP monitor (Spacelabs Healthcare, Issaquah, WA, USA) was set to obtain BP readings at 30minute intervals during the day and 60-minute intervals during the night. The following data were collected for each patient: heart rate, systolic BP (SBP), diastolic BP (DBP), mean BP (MBP) and pulse pressure. The dipping of SBP, DBP and MBP during the nocturnal period compared with the diurnal period was calculated as follows: dipping (%) = (diurnal BP − nocturnal BP)/diurnal BP × 100. A nondipper pattern was diagnosed if the nocturnal decrease in SBP was inferior to 10% compared with the diurnal period. The standard deviation (SD) of BP was collected for each patient and the coefficient of variation (cVar) of BP was calculated.
Echocardiography included M-mode, two-dimensional, pulsed Doppler and tissue Doppler imaging recordings. M-mode allowed the measurement of LV dimensions. LV ejection fraction (LVEF) was assessed using Simpson's modified biplane method. Pulsed Doppler was used to measure peak early (E) and late (A) diastolic velocities of the mitral flow. Pulsed tissue Doppler imaging of the lateral LV wall allowed the measurement of systolic (S) and early diastolic (Ea) velocities. Right heart catheterization using a Swan-Ganz catheter allowed the recording of pressure from the right atrium, right ventricle and pulmonary artery, and pulmonary capillary wedge pressure. Cardiac output was measured in triplicate using the thermodilution method.
FAP-related haemodynamic impairment [25] was diagnosed if at least one of the following criteria was observed: LVEF less or equal to 50%; pulmonary capillary wedge pressure greater than 12 mmHg; E/Ea ratio greater than 8; E/A ratio greater than 2.
Cardiac infiltration was quantified by measuring interventricular septum thickness and calculating relative wall thickness (RWT); RWT = (2*PWTd)/LVIDd, where PWTd is posterior wall thickness and LVIDd is LV internal diameter at end-diastole. Patients with arterial hypertension had been excluded at entry (see above) and no patient had aortic stenosis. Cardiac thickening was confirmed if: the interventricular septum thickness was greater than 12 mm; the RWT was greater than 0.42.
Conduction disorders were evaluated by surface electrocardiogram and electrophysiological study. The His bundle potential was recorded by a quadripolar lead and the time between the His bundle potential and ventricular depolarization was measured (HV interval). Conduction disorders were defined by one of the following criteria: PR interval greater or equal to 200 ms; complete bundle branch block (QRS duration ≥ 120 ms); HV interval greater than 70 ms; patients implanted with a pacemaker. The autonomic nervous system was evaluated in a subgroup of 32 over 49 patients according to our routine protocol, based on: 24-hour Holter electrocardiogram with measurement of SD of normal-to-normal RR intervals (abnormal if < 100 ms); and 123-metaiodobenzylguanidine (123-MIBG) cardiac scintigraphy (heart/mediastinum ratio at 4 hours; normal value > 1.6) [17, 26, 27] .
Statistical analysis
Continuous variables are presented as mean ± SD. Categorical variables are presented as frequencies and percentages. Analysis of BPV included circadian BPV (dipping status, level of dipping), SD of BP and cVar. The cVar was calculated as follows: (SD × 100)/mean. To comply with the mathematical formula for cVar and the level of dipping, the relationship between these two variables used the absolute value of dipping. Comparisons between normal continuous variables were performed using the Mann-Whitney test. Categorical unpaired variables were compared using Fisher's exact test. Correlation between continuous variables was measured by Spearman's test. In order to assess BP level as a potential confounding factor, the relationship between the dipping level and the presence/absence of conditions was analysed by a multiple logistic regression. Levels of SBP and dipping entered the analysis as independent variables and the presence/absence of condition entered the analysis as the dependent variable. Results of the multiple logistic regression are expressed as coefficient ± standard error (Coeff) and P value. A value of P < 0.05 was considered statistically significant. The statistical software used was Statview (version 5.0; SAS Institute, Inc., Cary, NC, USA). 
Results

Comparison between familial amyloid polyneuropathy and control groups
A non-dipping pattern was documented in 39 over 49 FAP patients (80%) and in 17 over 49 controls (35%; P < 0.0001) (Tables 1 and 2; Fig. 1 ). Compared with controls, FAP patients displayed significantly lower BP values during the diurnal period, whereas nocturnal BP values were similar. Over 24 hours, FAP patients also displayed a lower cVar of BP than control subjects. If diurnal and nocturnal periods were considered separately, no statistically significant differences were found between FAP patients and controls. In order to identify the level of BP as a potential confounding factor, the level of dipping was correlated to the average value of SBP and to a variable independent of average BP level (cVar of SBP), in the overall population (control + FAP, n = 98) and in both subgroups. There was a weak positive relationship between SBP and percentage of dipping in the overall population (r = 0.2, P = 0.03), thus explaining 4% of the percentage of dipping (r 2 = 0.04). This correlation was not statistically significant if FAP patients (r = 0.16; P = 0.27) and controls (r = −0.03; P = 0.8) were considered separately. The absolute level of dipping was strongly correlated with the cVar of SBP, not only in the overall population (n = 98, r = 0.69; P < 0.0001) but also in the FAP group (n = 49, r = 0.58; P < 0.0001) and the control group (r = 0.73; P < 0.0001) ( Fig. 2 ).
Blood pressure profile according to cardiac involvement
Extensive characteristics of FAP patients are displayed in Table 3 . The non-dipper profile was found in 31 over 40 patients with a polyneuropathy disability (PND) score I, in four over five patients with a PND score II, in two over two patients with a PND score III and in two over two patients with a PND score IV. A non-dipping pattern was documented in 22 over 28 FAP patients (79%) with the Val30Met mutation and in 17 over 21 FAP patients (81%) with other mutations (P not significant). BP levels (SBP, DBP and MBP) and variability (dipping of SBP, DBP and MBP) did not differ significantly according to mutation type (Val30Met versus other mutations).
Haemodynamic impairment was documented in 25 over 49 patients (51%) -namely, LVEF less or equal to 50% (n = 8), pulmonary capillary wedge pressure greater than 12 mmHg (n = 8), E/Ea ratio greater than 8 (n = 17) and E/A ratio greater than 2 (n = 3) -bearing in mind that one patient might have several criteria. Patients with haemodynamic impairment exhibited a non-dipping pattern more frequently than patients without haemodynamic impairment (92% vs 67%, respectively; P = 0.04). Multiple logistic regression also showed that haemodynamic impairment was associated with the level of dipping (Coeff = 10.77 ± 4.86; P = 0.03) but not with the level of SBP (Coeff = 0.02 ± 0.03; p = 0.4). The percentages of SBP, DBP and MBP dipping were higher in patients without haemodynamic impairment than in patients with haemodynamic impairment (Table 4 ). In FAP patients, the percentage of SBP dipping was correlated to the E/Ea ratio (r = -0.33; P = 0.04) but not to pulmonary capillary wedge pressure or the E/A ratio. Tissue Doppler imaging analysis showed that the S wave was also correlated to dipping of SBP (r = 0.42; P = 0.02).
A thickened cardiac wall was documented in 25 over 49 patients (51%) and was due to an interventricular septum thickness greater than 12 mm (n = 2), an abnormal RWT (n = 6) or both (n = 17). The percentage of patients with a non-dipper profile did not differ significantly between patients with and without cardiac infiltration (88% vs 68%, respectively; P = 0.15). Multiple logistic regression showed that cardiac thickening was associated with the level of dipping (Coeff = 9.44 ± 4.7; P = 0.047) but not with the level of SBP (Coeff = 0.04 ± 0.03; P = 0.2). The percentages of SBP and MBP dipping were higher in patients without infiltration than in patients with infiltration ( Table 4 ). The percentage of SBP dipping was not correlated to interventricular septum thickness, posterior wall thickness or RWT (P = 0.25, 0.13 and 0.08, respectively). Conduction disorders were documented in 21 over 49 patients (42%). First-degree atrioventricular block was documented in eight patients, complete bundle branch block in three patients and prolonged HV interval greater than 70 ms in seven patients. Eight patients had been previously implanted with a pacemaker. The non-dipper BP profile was more common in patients with conduction disorders than in patients without conduction disorders (95% vs 68%, respectively; P = 0.03). Multiple logistic regression showed that conduction disorders were not significantly associated with the level of dipping (Coeff = 7.97 ± 4.26; P = 0.06) or with the level of SBP (Coeff = 0.03 ± 0.03; P = 0.3). The percentage of SBP dipping was not correlated to the PR interval, QRS interval or HV interval (P = 0.24, 0.34 and 0.31, respectively).
Cardiac denervation was documented in 26 over 32 patients (81%). The non-dipping profile occurred in 21 over 26 patients (81%) with cardiac denervation and in three over six patients (50%) without cardiac denervation (p = 0.15). Dipping status and cardiac autonomic status overlapped in 24 over 32 patients (75%). Multiple logistic regression showed that cardiac denervation was not significantly associated with the level of dipping (Coeff = 7.37 ± 1.16; P = 0.28) or with the level of SBP (Coeff = 0.04 ± 0.31; P = 0.31). Finally, Table 4 shows that the BP dipping did not differ significantly according to cardiac denervation.
Interaction between blood pressure variability and cardiac amyloidosis severity
Conduction disorders, thickened cardiac walls and functional restrictive pattern were the three criteria reflecting the severity of cardiac involvement. In our FAP patients (n = 49), 12 patients had three criteria, 11 patients had two criteria, 13 patients had one criterion and 13 patients displayed neurological symptoms without any criteria for severe cardiac amyloidosis. A non-dipper profile was documented in eight over 13 patients (62%) with 0 criterion, nine over 13 patients (69%) with one criterion, 11 over 12 patients (91%) with two criteria and 12 over 12 patients (100%) with three criteria for cardiac amyloidosis. Compared with controls, SBP dipping was lower in each of these subgroups of FAP patients (Fig. 3) . SBP dipping was lower in patients with three criteria than in patients with no criteria or one criterion (5.8% and 5.9% vs -3.8%; P = 0.03 and 0.01, respectively).
Discussion
The present retrospective study included 49 FAP patients from a European population with the Val30Met mutation (57%) and free from arterial hypertension, and 49 age-and sex-matched normotensive controls. BPV was lower in the FAP group than in the control group. Impaired BPV was documented in 80% of FAP patients. Abnormal BPV was associated with impaired haemodynamic status, cardiac wall thickening and conduction disorders. Impaired BPV was observed in the early stages of FAP and was more pronounced in patients with severe cardiac amyloidosis. These results suggested that impaired BPV was associated with several components of cardiac amyloidosis due to FAP and reflected the severity of cardiac infiltration. Circardian BPV is related to the imbalance between cardiac output and systemic vascular resistance. During the nocturnal period, cardiac output decreases, whereas systemic vascular resistances do not change or are higher than during the diurnal period, resulting in a drop in BP [2] . A cutoff value of 10% has been used since 1988 to define dippers and non-dippers [28] . The non-dipping pattern is commonly found in one fourth to one third of the general healthy Values are expressed as mean and standard error of the mean. Control group versus familial amyloid polyneuropathy (FAP) group, P < 0.0001; control group versus no criteria, P = 0.01; control group versus one criterion, P = 0.005; control group versus two criteria, P = 0.0003; control group versus three criteria, P < 0.0001; no criteria versus three criteria, P = 0.03; one criterion versus three criteria, P = 0.01. population and is associated with age, sex and hypertensive status [29] . The 35% value of non-dippers documented in our control group is thus at the upper limit of the published values [29] . This may be explained by the fact that we did not study healthy volunteers but patients with suspicion of arterial hypertension, in whom this diagnosis was ruled out. In patients with systemic hypertension, the nondipping pattern is due to a blunted decrease in BP during the night (related to an increase in systemic vascular resistance [30] or a blunted decrease in cardiac output during the night [31] ).
The non-dipping pattern has been constantly associated with a worse prognosis in systemic hypertension [10, 32] and diabetes [11, 33] , and also among the general population [34] . In hypertension, a non-dipping profile is associated with impaired endothelial function [35] and a higher LV mass index [12] . A non-dipping profile is also associated with an increased risk of cardiovascular mortality [34] .
To the best of our knowledge, only a few studies have documented BPV in cardiac FAP, all of which were performed on FAP patients with the Val30Met mutation by the same Portuguese team. In a large cohort (n = 212) with various stages of autonomic impairment, Carvalho et al. [19] demonstrated that the dipping level progressively decreases as dysautonomia progresses. They also showed that FAP induces both early parasympathetic failure and delayed sympathetic failure [5, 18] . Our results confirmed that variables integrating circadian variability, such as the level of dipping and the global cVar of BP, are decreased in FAP. A second study by the same team demonstrated that secretions of noradrenaline and adrenaline in response to orthostatic challenge were low in FAP due to the Val30Met mutation and that this was associated with a blunted rise in total peripheral resistance during supine stress [36] . Moreover, BP overshoot after tilt reversal was higher in FAP patients than in control subjects [37] . These impaired BP responses during orthostatic challenge or tilt reversal may paradoxically increase BPV. Conversely, BPV evaluated during relative short periods of time (diurnal or nocturnal cVar) did not differ significantly between the FAP and control groups. Finally, our data confirmed that the nondipping pattern was due to a blunted rise of BP during the diurnal period compared with controls, and not to a blunted decrease in BP during the night. This potential physiopathological mechanism would negatively mirror those described in systemic hypertension. In our study, a non-dipping profile was documented in 22 over 28 FAP patients with the Val30Met mutation (79%), which confirms previous findings [19] . Moreover, we also documented the same high prevalence of the non-dipping profile in FAP patients with other types of mutation (17/21, 81%). Cardiac denervation was precisely assessed in a subgroup of 32 patients by using classic heart rate variability and MIBG scintigraphy criteria. Interestingly, the dipping status and the cardiac autonomic status overlapped in 24 over 32 patients (75%).
In keeping with previous findings [19] , our study also documented that impaired BPV may occur early in the course of the disease. Indeed, the non-dipping profile was documented in patients with few specific criteria for cardiac involvement (no criteria or one criterion). However, BPV values markedly differed among FAP patients and one new finding of our study was that cardiac denervation was not the only factor associated with impaired BPV. The amount of cardiac involvement appeared to play a significant role. Indeed, BP dipping was lower and even reversed in patients with three criteria for cardiac amyloidosis. Taken together, these results suggested that BPV decreased in a two-step manner in FAP: a first step related to early dysautonomia; and a second step associated with the severity of cardiac amyloidosis. Interestingly, non-dipper hypertensive patients display higher cardiac remodelling compared with dipper patients, as assessed by echocardiography (LV mass, interventricular septum and left atrial diameter), despite similar BP values [32] .
Limitations and implications
This was a single-centre, cross-sectional study. Selection bias was minimized as we only excluded patients with systemic hypertension from the analysis. The results pertained strictly to our European population with a high prevalence of the Val30Met mutation (57%). However, a large panel of different mutations was represented in our cohort. Finally, the absence of a significant association between dipping status and cardiac involvement variables and the discrepancy between statistical analyses may reflect a lack of statistical power, thus preventing us to draw firm conclusions on these analyzes.
It is suggested that BPV may be a promising, non-invasive tool reflecting the severity of cardiac amyloidosis. Evaluation of BPV is a recognized, non-invasive, prognostic tool in various cardiovascular diseases [9] . Thus, further studies are needed to test this hypothesis specifically in FAP.
Conclusion
In our European population with the Val30Met mutation (57%) and free from arterial hypertension, the present retrospective study documented that 80% were non-dipper patients. This was mainly explained by a blunted rise in BP during the diurnal period. In FAP, SBP dipping was associated with impaired haemodynamic status, cardiac wall thickening and conduction disorders. Impaired BPV occurred early in FAP and was more pronounced in severe cardiac amyloidosis. BPV may be a promising, non-invasive tool reflecting the severity of cardiac amyloidosis due to FAP. The prognostic implications of our results deserve further studies.
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